证券代码：688506 证券简称：百利天恒 公告编号：2026-002 四川百利天恒药业股份有限公司 关于取得金融机构股票回购专项贷款承诺函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、股份回购方案基本情况 1、贷款承诺额度：不超过 1.8 亿元人民币。 2、贷款期限：3 年。 3、贷款用途：专项用于回购公司股份。 本次股票回购具体贷款相关事项以双方正式签订的股票回购贷款合同为准。 三、其他说明 本次收到贷款承诺函可为公司本次回购股份提供融资支持，具体贷款事宜以双 方最终签订的贷款合同为准。本次取得金融机构股票回购贷款承诺函不代表公司对 回购金额的承诺，具体回购股份的数量以实际回购的股份数量为准。 公司将根据后续市场情况及资金到位情况，在回购期限内实施本次股份回购方 案，并按照相关法律法规的规定及时履行信息披露义务。敬请广大投资者注意投资 四川百利天恒药业股份有限公司（以下简称"公司"）于 2025 年 12 月 30 日召 开了第五届董事会第五次会议，审议通过了《关于以集中竞价交易方式回购公司股 份方案的议 ...

Group 1: Overall Industry Outlook - In 2026, the pharmaceutical industry is expected to experience a surge in innovative drugs, a recovery in the CXO sector, transformation in traditional Chinese medicine, contraction of retail pharmacies, restructuring of hospitals, and a wave of mergers and acquisitions, leading to increased industry differentiation and stronger players remaining dominant [1] Group 2: Innovative Drugs - A total of 76 innovative drugs were approved in 2025, marking a 58% increase from the previous year, with over 150 licensing transactions totaling more than $130 billion, indicating robust growth in China's innovative drug sector [3] - Approximately 20 major innovative drugs are anticipated to be approved in China in 2026, covering various therapeutic areas including oncology and rare diseases, with notable examples such as BL-B01D1 for esophageal squamous carcinoma [3][4] Group 3: CXO Sector - The CXO (Contract Research Organization) industry is experiencing a recovery driven by external factors such as U.S. interest rate cuts and increased R&D investments from multinational pharmaceutical companies, alongside domestic demand for CRO services [5][6] - The penetration rate of outsourcing in areas like ADCs and oligonucleotides is expected to rise to 65%, with companies like WuXi AppTec and Kelun Biotech showing strong growth in these segments [6] Group 4: Traditional Chinese Medicine - The Chinese medicine sector is entering an era of refined management, driven by policy upgrades and market innovations, with a focus on quality and cost balance in procurement [7][9] - By the end of 2026, China aims to establish 180 domestic and 30 international standards for traditional Chinese medicine, with the market expected to exceed 1 trillion yuan for the first time in 2024 [9] Group 5: Medical Devices - The medical device industry is shifting from price suppression to innovation-driven growth, with domestic companies rapidly advancing in high-end imaging, surgical robots, and AI medical devices [10] - Chinese medical device companies are increasingly expanding into international markets, with a notable rise in export volumes expected by 2026 [10] Group 6: Retail Pharmacies - The offline pharmacy sector is projected to contract significantly due to the growth of O2O and B2C models, with over 15,975 stores closing by September 2025, reflecting a 73% year-on-year increase in closures [12][13] Group 7: Private Hospitals - Private hospitals are facing severe challenges, with an average of 1.4 closures per day in 2024, and this trend is expected to continue into 2026 due to regulatory pressures and financial difficulties [14][15]

Core Viewpoint - The drug ADCiza-bren (BL-B01D1), developed by Sichuan BaiLi Tianheng Pharmaceutical Co., Ltd., has been included in the priority review process by the Center for Drug Evaluation (CDE) for a new indication in treating recurrent or metastatic esophageal squamous cell carcinoma that has failed previous PD-1/PD-L1 monoclonal antibody combined with platinum-based chemotherapy [1]. Group 1 - ADCiza-bren is the first ADC drug to achieve positive results in both progression-free survival (PFS) and overall survival (OS) in a Phase III clinical trial for esophageal cancer [1]. - The drug has previously been included in the priority review process for its first indication, advanced nasopharyngeal carcinoma, which was accepted by CDE on November 21 of the same year [1]. - As of now, ADCiza-bren has received seven breakthrough therapy designations from CDE and one from the U.S. Food and Drug Administration (FDA) [2].

Group 1 - The article highlights a significant increase in stock prices for various biotech companies, with Chengdu XianDao and Rejing Bio rising over 12%, and several others showing gains of 3% to 9% [1] - The Super Flu is spreading globally, with the U.S. reporting over 7.5 million cases this flu season, leading to over 80,000 hospitalizations and 3,100 deaths, primarily driven by the H3N2 virus variant [1] - A new national medical insurance drug list has been implemented, adding 114 new drugs, including 50 first-class new drugs, marking a record high in both quantity and proportion [1] Group 2 - The latest batch of centralized procurement will be implemented in February 2026, covering 55 essential drugs, including those for chronic diseases and pediatric use [2] - The medical device price governance will enter a new phase in 2026, with some products seeing price reductions exceeding 97%, establishing a minimum price threshold [2] - The healthcare service landscape is improving, with new regulations mandating that primary healthcare institutions must equip at least five categories of antihypertensive drugs by March 2026 [2]

Group 1: Market Performance - Hong Kong's innovative drug ETF (159570) surged by 3%, with a trading volume exceeding 1.5 billion yuan, following a net inflow of over 62 million yuan today after a previous inflow of 430 million yuan [1][3] - As of January 6, the latest scale of the Hong Kong innovative drug ETF reached over 23.3 billion yuan, leading its peers in the same category [1] Group 2: Economic Signals - Federal Reserve Governor Milan indicated that upcoming economic data may support further interest rate cuts, with expectations of a reduction exceeding 100 basis points this year [3] - Wall Street analysts suggest that if the U.S. unemployment rate rises to 4.7% by December 2025, the Fed may cut rates by 25 basis points this month [3] Group 3: Company Developments - Brain-computer interface "unicorn" Strong Brain Technology completed a financing round of 2 billion yuan, second only to Musk's Neuralink [3] - AI pharmaceutical company Insilico Medicine announced a long-term collaboration with Siveya for anti-tumor drug development, with a total deal value of 888 million USD [3] Group 4: New Drug Approvals - On January 6, BeiGene announced that its self-developed BCL2 inhibitor, Baiyueda® (sotucumab), received conditional approval from the National Medical Products Administration [3] - Shiyao's SYS6017 has initiated Phase II clinical trials for the prevention of shingles [3] Group 5: Investment Insights - Zhongtai Securities predicts that the pharmaceutical sector's opportunities in 2025 will focus on innovation and industry upgrades, with investment strategies continuing into 2026 [5] - The report emphasizes the importance of "innovative drugs and industry chains, demand recovery, and AI" as key investment dimensions [5] Group 6: J.P. Morgan Healthcare Conference - The 44th J.P. Morgan Healthcare Conference is set to take place from January 12 to 15, 2026, in San Francisco, attracting over 8,000 global participants [6] - The conference will feature over 500 listed companies and thousands of startups, focusing on "capital + strategy" discussions [6] Group 7: Industry Trends - Three major trends are highlighted for 2026: the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the emergence of new market forces [7] - The report notes that over 20 gene editing companies will showcase breakthroughs in CAR-T and base editing at the conference [7] Group 8: MNC Engagement - Multinational corporations (MNCs) are willing to pay higher prices for innovative drugs from China, with the average total package for drugs purchased from China being 2.76 billion USD, compared to 1.29 billion USD for those from overseas [8] - The willingness of MNCs to pay a premium for Chinese innovations is driven by the need to fill significant pipeline gaps due to impending patent expirations [8] Group 9: Investment Focus - Investment strategies should focus on companies with strong clinical development capabilities and those in popular therapeutic areas such as ADCs, GLP-1, and dual antibodies [11] - Companies that can produce high-quality late-stage clinical assets are likely to attract MNC interest [11] Group 10: Key Therapeutic Areas - The report identifies key therapeutic areas for investment, including ADCs, GLP-1, dual antibodies, and neuroscience, emphasizing the need for innovative platforms and clinical data superiority [12]

Core Viewpoint - Bailitianheng (688506.SH) announced that its self-developed, first-in-class, new concept, and the only EGFR×HER3 dual-target ADC (injectable iza-bren) has been included in the priority review list by the National Medical Products Administration's Center for Drug Evaluation (CDE) [1] Group 1 - The drug iza-bren is the first EGFR×HER3 dual-target ADC globally to be included in the priority review list [1]

今日焦点 20CM两连板三博脑科：目前不涉及脑机接口产品的研发、生产及销售 三博脑科公告称，公司股票于2026年1月5日、1月6日连续两个交易日内收盘价格涨幅偏离值累计超过 30%，属于股票交易异常波动情形。公司是以神经专科为特色的医疗服务集团，下属院区主要为患者提 供以高精尖神经外科为主的综合医疗服务。公司目前不涉及脑机接口产品的研发、生产及销售，神经调 控技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影响，敬请注意投资风险。 2连板翔宇医疗：截至2025年末脑机接口相关产品尚未实现规模化销售 翔宇医疗发布异动公告，近期资本市场对人脑工程、脑机接口等概念关注度较高，相关板块股价涨幅较 大。公司目前主要聚焦非侵入式脑机接口技术，覆盖作业疗法、运动疗法、认知言语、吞咽等康复全场 景布局，与当前国际上的侵入式脑机接口技术路线存在差异。公司在脑机接口方面的投入，目前在技 术、产品、渠道市场等方面形成一定的布局，但招投标和销售等具有滞后性，截至2025年末，相关产品 尚未实现规模化销售，营收占比较小。 6天4板中国卫通：目前股价已处于历史最高点，已严重脱离基本面存在短期大幅下跌的风险 中国卫通发布股票交易风 ...

Core Viewpoint - The National Medical Products Administration (NMPA) has prioritized the review of Iza-bren (BL-B01D1, an EGFR/HER3 dual antibody ADC) for the treatment of recurrent or metastatic esophageal squamous cell carcinoma in patients who have failed previous PD-1/PD-L1 monoclonal antibody combined with platinum-based chemotherapy [1] Group 1 - Iza-bren is the second indication to be prioritized for review, with the first being nasopharyngeal carcinoma, which was prioritized in September 2025 [1] - The new drug application for the nasopharyngeal carcinoma indication was accepted by the NMPA in November 2025 [1] - In the same month, the Phase III study (BL-B01D1-305) for the treatment of esophageal squamous cell carcinoma achieved significant improvements in both progression-free survival (PFS) and overall survival (OS) in its pre-specified interim analysis [1]

Core Viewpoint - The article highlights that BaiLi TianHeng's dual antibody ADC, iza-bren (BL-B01D1), has been included in priority review by the CDE for the treatment of recurrent or metastatic esophageal squamous cell carcinoma in patients who have failed previous PD-1/PD-L1 monoclonal antibody combined with platinum-based chemotherapy [1] Group 1 - Iza-bren is the second indication to be included in priority review, following its first indication for nasopharyngeal carcinoma, which was prioritized in September 2025 [1] - The new drug application for the nasopharyngeal carcinoma indication was officially accepted by the CDE in November 2025 [1]

Core Viewpoint - Baili Tianheng (688506) announced that its self-developed, first-in-class EGFR×HER3 dual antibody ADC (injectable iza-bren) has been included in the priority review list by the National Medical Products Administration (NMPA) [1] Group 1 - Iza-bren is the world's first EGFR×HER3 dual antibody ADC to be included in the priority review list [1] - As of now, iza-bren has been recognized as a breakthrough therapy for recurrent or metastatic esophageal squamous cell carcinoma that has failed previous PD-1/PD-L1 monoclonal antibody combined with platinum-based chemotherapy [1] - The interim analysis for the Phase III clinical trial of iza-bren has achieved dual primary endpoints of progression-free survival (PFS) and overall survival (OS) [1] Group 2 - Iza-bren has two indications that have been included in the priority review list by the NMPA [1]